# EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial

Study · id `cardio:ct-nct03932721` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03932721](<https://clinicaltrials.gov/study/NCT03932721>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03932721

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

## Technical summary

Registry record NCT03932721. Randomized; single masking; primary purpose diagnostic. Start 2018-10-01 (actual); primary completion 2021-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose diagnostic
- Phase: Phase 4
- Enrolled: 110 participants (enrolled count; ClinicalTrials.gov record NCT03932721, source copy `cardio:ctgov-nct03932721-2023-03-09`, retrieved 2026-10-26)
- Started: 2018-10-01 (actual) (ClinicalTrials.gov record NCT03932721, source copy `cardio:ctgov-nct03932721-2023-03-09`, retrieved 2026-10-26)
- Primary completion: 2021-06-30 (actual) (ClinicalTrials.gov record NCT03932721, source copy `cardio:ctgov-nct03932721-2023-03-09`, retrieved 2026-10-26)
- Completion: 2021-10-30 (actual) (ClinicalTrials.gov record NCT03932721, source copy `cardio:ctgov-nct03932721-2023-03-09`, retrieved 2026-10-26)
- Countries: Brazil (ClinicalTrials.gov record NCT03932721, source copy `cardio:ctgov-nct03932721-2023-03-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03932721-2023-03-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial
- Acronym: EXCEED-BHS3
- Condition: Dyslipidemia Associated With Type II Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 2
- Condition: Hypertension Arterial
- Intervention (Drug): Evolocumab 140 MG/ML
- Lead sponsor: University of Campinas, Brazil
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Evolocumab (`cardio:evolocumab`)

## Provenance

Content hash: 7980ed1370b3d91b90ebcee7919a649904b67489ca5aeeb741cb0c037ad02977
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
